NCT00526799 - Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

August 31, 2010

Conditions

Ovarian Cancer

Interventions

DRUG

Sorafenib

"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"

DRUG

Topotecan

3.5mg/m2 weekly, 3 weeks on and one week off.

Trial Locations (8)

Schwartz Gynecologic Oncology, PLLC, Brightwaters

Indiana University Simon Cancer Center, Indianapolis

St. Vincent Hospital Cynecologic Oncology, Indianapolis

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Medical Consultants, P.C., Muncie

Oncology Hematology Associates of SW Indiana, Evansville

Arnett Cancer Care, Lafayette

Medical & Surgical Specialists, LLC, Galesburg